You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Human Performance Optimization

    SBC: HVMN Inc.            Topic: SOCOM17C001

    During altitude-induced hypoxia, operator cognitive and physical capacity degrades, compromising individual and team performance. Cognitive degradation is linked to falling brain energy levels, increased reliance on anaerobic energy production and lactate accumulation. Ketones are the evolutionary alternative substrate to glucose for brain metabolic requirements; previous studies demonstrated that ...

    STTR Phase II 2019 Department of DefenseSpecial Operations Command
  2. Human Performance Optimization

    SBC: REJUVENATE BIO INC            Topic: SOCOM17C001

    Special OperationsForces (SOF)are an integral aspect of the US military. SOF operators are among the most elite and highly qualified individuals in the U.S.military. As such, extraordinary physical and mental demands are placed upon them to excel in extreme environments for extended periods of time. This unrelenting cycle of combat deployments and intense pre-deployment training shortens the funct ...

    STTR Phase II 2019 Department of DefenseSpecial Operations Command
  3. Visual Relative Navigation via Intelligent Ephemeral Relationships (VRNIER)

    SBC: TOYON RESEARCH CORPORATION            Topic: ST18C006

    As unmanned aircraft systems (UAS) become more prevalent there is an increasing desire to automate UAS navigation and control. To enable future UASs to perform a wider variety of missions, the they must be able to complete autonomous relative navigation to accomplish missions. Current technologies rely heavily on GPS measurements, which are undesirable since GPS signals may be unavailable in many ...

    STTR Phase I 2019 Department of DefenseDefense Advanced Research Projects Agency
  4. Pathogen Classification Tool (PaCT)

    SBC: Stottler Henke Associates, Inc.            Topic: ST18C002

    Stottler Henke proposes PaCT, leveraging our related past work in computer vision and machine learning. Drawing from techniques used in ExPATSS, a Phase II SBIR effort slated for transition to the Naval fleet, PaCT will perform bacterial characterization using features derived from the phenotype of the bacteria. PaCT will predict bacterial characteristics such as pathogenicity, antibiotic resistan ...

    STTR Phase I 2019 Department of DefenseDefense Advanced Research Projects Agency
  5. Development of Autonomous Glycemic Control Mechanism for Patients Suffering Glycemic Abnormalities as a Result of Critical Illnesses

    SBC: PROFUSA, INC.            Topic: ST18C004

    The use of continuous glucose monitors can be an invaluable management tool for patients afflicted by glycemic variability due to critical illness or trauma. Maintaining stable glucose levels enhances health and lowers care costs, and individuals equipped with continuous glucose data have significantly improved outcomes. Profusa has developed highly miniaturized, injectable, tissue-like, glucose s ...

    STTR Phase I 2019 Department of DefenseDefense Advanced Research Projects Agency
  6. Methane Harvesting for Seafloor Generation

    SBC: Makai Ocean Engineering, Inc.            Topic: ST18C005

    Autonomous underwater vehicles (AUVs) are critical to DoD undersea missions including the future capabilities for sea and sub-sea forces communication and connectivity. AUV mission lengths are currently limited to 24 hours due to the prohibitive battery storage and AUV energy demands. Makai Ocean Engineering, with the University of Hawaii’s Hawaii Natural Energy Institute (HNEI), proposes to dev ...

    STTR Phase I 2019 Department of DefenseDefense Advanced Research Projects Agency
  7. Marburg Virus Prophylactic Medical Countermeasure

    SBC: Flow Pharma, Inc.            Topic: CBD18A002

    Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  8. Circulating Diagnostic Markers of Infectious Disease

    SBC: PATHOVACS INCORPORATED            Topic: CBD18A001

    The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-d ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  9. Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

    SBC: CFD Research Corporation            Topic: CBD18A001

    In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
  10. Marburg Virus Prophylactic Medical Countermeasure

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: CBD18A002

    There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...

    STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government